Skip to main content
TipRanks
Go Ultimate75% OFF

Qlife Holding AB (QLIFE) AI Stock Analysis

0 Followers
SE:QLIFE

Qlife Holding AB

(Nasdaq OMX AB:QLIFE)

Select Model
Rating:38Underperform
Price Target:SEK 0.83â–¼(-13.52% Downside)
Action:reiterated
Date:11/14/26

Extremely weak financials with minimal revenue, negative equity, and cash outflows are the dominant factors. Bearish technical signals from price below DMAs and negative MACD add pressure, while negative P/E further weighs on the score.

Positive Factors
Recurring consumables modelCombining diagnostic instruments with single-use cartridges or reagents can create repeat purchasing as the installed base expands. This model gives Qlife a pathway to recurring revenue and greater customer retention, provided deployments and test utilization continue to grow.
Negative Factors
Small, declining revenue baseQlife remains at a very small revenue scale while TTM sales have declined and all major profitability measures are negative. This indicates that the company has not yet achieved operating scale or a sustainable cost structure, leaving earnings highly vulnerable to execution setbacks.

Qlife Holding AB (QLIFE) vs. iShares MSCI Sweden ETF (EWD)

-50%-25%0%25%50%75%100%125%SE:QLIFE-31.81%EWD+17.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 27.55M
Dividend Yield
―
Average Volume (3M)
74.73K
Price to Earnings (P/E)
-0.7
Beta (1Y)
1.41
Revenue Growth
142.55%
EPS Growth
73.84%
Country
Sweden
Employees
2
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Qlife Holding AB Business Overview & Revenue Model

Company Description

Operating as a medical technology firm, Qlife Holding AB (publ) specializes in the production and distribution of in-vitro diagnostic instruments and their associated chemical reagents. Their flagship offering is the Egoo.Health Platform, a comprehen...

How the Company Makes Money

Qlife Holding AB makes money primarily by commercializing its diagnostic platform and the associated consumables used to run tests. The core revenue model typically combines (1) sales or leasing of instrumentation (the analyzer/platform), and (2) rec...

Qlife Holding AB Financial Statement Overview

Summary

Minimal TTM revenue under 1M with negative growth, deeply negative margins, negative equity, high debt, and persistent cash burn signal severe distress and high financial risk.

Income Statement

15Very Negative

Balance Sheet

10Very Negative

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue798.00K324.00K50.00K244.00K17.99M39.61M
Gross Profit-7.01M-18.11M-158.00K-6.31M-10.75M44.54M
EBITDA-15.76M-18.11M-12.46M-150.50M-78.05M-35.13M
Net Income-17.47M-20.56M-55.98M-159.96M-93.14M-38.80M
Balance Sheet
Total Assets8.82M9.63M11.64M39.05M192.65M193.44M
Cash, Cash Equivalents and Short-Term Investments1.90M1.42M2.71M1.66M14.55M73.46M
Total Debt8.17M14.44M8.70M20.25M52.44M4.72M
Total Liabilities9.64M17.14M13.07M62.17M101.50M30.26M
Stockholders Equity-820.00K-7.51M-1.43M-23.12M91.15M132.50M
Cash Flow
Free Cash Flow-8.27M-21.49M-54.17M-62.64M-90.67M-52.82M
Operating Cash Flow-15.59M-21.49M-37.37M-41.80M-47.73M-26.05M
Investing Cash Flow00-16.80M-20.84M-42.94M-26.77M
Financing Cash Flow14.27M20.19M55.23M49.00M32.73M106.02M

Qlife Holding AB Technical Analysis

Technical Analysis SentimentNegative
Last Price0.95

Price Trends

50DMA1.31Negative
100DMA1.58Negative
200DMA1.79Negative

Market Momentum

MACD-0.10Negative
RSI42.39Neutral
STOCH57.56Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:QLIFE, the sentiment is Negative. The current price of 0.95 is below the 20-day moving average (MA) of 1.00, below the 50-day MA of 1.31, and below the 200-day MA of 1.79, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 42.39 is Neutral, neither overbought nor oversold. The STOCH value of 57.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:QLIFE.

Qlife Holding AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:QLIFE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CEVISE:CEVI83OutperformSEK 4.83B35.0315.23%1.36%1.95%-8.91%
SE:SECT.BSE:SECT.B78OutperformSEK 62.28B97.6130.26%0.72%13.94%5.70%
SE:SEZISE:SEZI55NeutralSEK 528.24M-5.42-35.44%―18.56%28.11%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:ACARIXSE:ACARIX45NeutralSEK 201.21M-5.10-96.06%―40.61%32.63%
SE:SCIBSE:SCIB40UnderperformSEK 130.47M-0.69-415.20%―54.94%47.64%
SE:QLIFESE:QLIFE38UnderperformSEK 27.55M-0.711852.00%―142.55%73.84%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%SE:QLIFESE:CEVISE:SEZISE:SCIBSE:SECT.BSE:ACARIXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:QLIFE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:QLIFEQlife Holding AB0.95-0.53-35.89%
SE:CEVICellaVision AB202.5048.3331.35%
SE:SEZISenzime AB3.36-1.72-33.86%
SE:SCIBSciBase Holding AB9.24-9.85-51.61%
SE:SECT.BSectra AB Class B319.2043.8015.90%
SE:ACARIXAcarix AB0.16-0.11-40.66%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026